Drugs / Peginterferon Lambda-1a
Peginterferon Lambda-1a
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01708889 | Sep 2012 → Feb 2013 | chronic hepatitis B virus infection, chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00565539 | Dec 2007 → Oct 2009 | chronic hepatitis C virus infection | ZymoGenetics | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT04388709 | Sep 2020 → Feb 2021 | COVID-19 | Icahn School of Medicine at Mount Sinai | Withdrawn | No outcome recorded |
| Phase 2 | NCT04343976 | Jun 2020 → Jul 2021 | COVID-19 | Raymond Chung | Terminated | No outcome recorded |
| Phase 2 | NCT04354259 | May 2020 → Aug 2022 | COVID-19 | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT04331899 | Apr → Aug 2020 | COVID-19 | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT04534673 | Apr 2020 → Feb 2023 | COVID-19 | Soroka University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02765802 | Oct 2016 → Jul 2018 | hepatitis D virus infection | Eiger BioPharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01795911 | Mar 2013 → Apr 2014 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01309932 | Mar 2011 → Jul 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01204762 | Nov 2010 → Dec 2013 | hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01001754 | May → Nov 2010 | chronic hepatitis C virus infection | ZymoGenetics | Unknown | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT05070364 | Dec 2021 → Jun 2024 | hepatitis D virus infection | Eiger BioPharmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT04967430 | Aug 2021 → Mar 2022 | COVID-19 | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 3 | NCT01866930 | Jul 2013 → Aug 2015 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 3 | NCT01741545 | Mar 2013 → Jan 2015 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01754974 | Mar 2013 → Sep 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01718158 | Jan 2013 → Oct 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01616524 | Jul 2012 → Jun 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01598090 | Jun 2012 → Feb 2015 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01447394 | Mar 2012 → Mar 2014 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-04-19 | Bristol-Myers Squibb | Investigational Compound Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Flu-Like and Musculoskeletal Symptoms in Phase IIb Study in Treatment-Naïve Genotype 2 or 3 Hepatitis C Patients bms.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon Lambda-1a | “BACKGROUND & AIMS: Peginterferon lambda-1a (lambda) is a Type-III interferon, which, like alfa interferons, has antiviral activity in vitro against hepatitis B virus (HBV) and...” PMID 26739688 ↗ Dec 201510“BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2” NCT01708889 ↗ |
| Known as | BMS-914143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01708889 ↗ |
| Known as | Lambda | “BACKGROUND & AIMS: Peginterferon lambda-1a (lambda) is a Type-III interferon, which, like alfa interferons, has antiviral activity in vitro against hepatitis B virus (HBV) and...” PMID 26739688 ↗ Dec 20153“a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis” PMID 33785743 ↗ Mar 2021 “pegylated interferon-lambda-1a (Lambda)/ribavirin (RBV)/daclatasvir (DCV)” PMID 28282271 ↗ Feb 2017 “180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection” NCT05070364 ↗ |
| Known as | PEG-interferon lambda | “PEG-rIL-29 (also known as PEG-interferon lambda) is a unique Type III interferon molecule” NCT01001754 ↗ |
| Known as | PEG-rIL-29 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00565539 ↗ |
| Known as | pegIFNλ | “Pegylated Interferon Lambda (pegIFNλ)” NCT01309932 ↗ |
| Known as | Pegylated interferon lambda | “Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7” NCT04534673 ↗ |
| Known as | Pegylated interferon lambda (pegIFNλ) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01616524 ↗ |
| Known as | Pegylated Interferon Lambda-1a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01866930 ↗ |
| Known as | PEGylated recombinant interleukin 29 | “PEGylated recombinant interleukin 29 (PEG-rIL-29)” NCT00565539 ↗ |
| Modality | Protein / enzyme biologic | “PEGylated recombinant interleukin 29 (PEG-rIL-29)” NCT00565539 ↗ |
| Route | Subcutaneous | “subcutaneous administration either weekly or every other week” NCT00565539 ↗ |